title: Rituximab for follicular non-Hodgkin lymphoma.
authors.forename: Elangovan
authors.initials: E
authors.lastname: Gajraj
authors.forename: Helen
authors.initials: H
authors.lastname: Chung
authors.forename: Carole
authors.initials: C
authors.lastname: Longson
authors.forename: Andrew
authors.initials: A
authors.lastname: Stevens
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab